← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT06267859

Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Respiratory Diseases
Sponsor Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 110
Sex ALL
Min Age 3 Days
Max Age 15 Years
Start Date 2023-11-08
Completion 2033-12-30
Interventions
The use of a combination of microelements and vitamins against the background of physiotherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of the clinical study is to clarify the course of common congenital, infectious, and non-infectious diseases in children living in Uzbekistan, and to develop methods for their treatment and rehabilitation. The main questions it aims to answer: * Analysis of common congenital diseases among children; * Analysis of commonly diagnosed bronchopulmonary and cardiovascular diseases among children; * Based on the results of the primary research, common diseases among children will be identified; * Analysis of existing treatment methods and their effectiveness; * Development of modern methods of treatment and rehabilitation of children.

Eligibility Criteria

Inclusion Criteria: * children from birth to 15 years; * children permanently residing in the territory where the clinical examination is carried out; * children included in the group of "frequently ill children"; * patients without severe chronic diseases. Exclusion Criteria: * Teenagers over 15 years old; * Patients with severe neurological and mental diseases; * Patients with endocrinological diseases; * Patients with long-term chronic somatic diseases; * Children without genetic pathologies.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}